Related references
Note: Only part of the references are listed.Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma
Maria Gavriatopoulou et al.
BLOOD CANCER JOURNAL (2020)
Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis
Shijia Zhang et al.
BLOOD CANCER JOURNAL (2020)
Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials
Somedeb Ball et al.
ANNALS OF HEMATOLOGY (2020)
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Peter M. Voorhees et al.
BLOOD (2020)
Once-weekly (70 mg/m2) vs twice-weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, ARROW, and CHAMPION-1 trials
Philippe Moreau et al.
CANCER MEDICINE (2020)
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial
Susanna J. Jacobus et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Multiple Myeloma, Version 3.2021
Shaji K. Kumar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma
Thierry Facon et al.
BLOOD (2019)
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
Sara Bringhen et al.
HAEMATOLOGICA (2019)
Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
Xavier Leleu et al.
CLINICAL CANCER RESEARCH (2019)
Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial
Ruth Wester et al.
HAEMATOLOGICA (2019)
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
Ola Landgren et al.
LEUKEMIA (2019)
Quadruplet KCRD (Carfilzomib, Cyclophosphamide, Lenalidomide and Dexamethasone) Induction for Newly Diagnosed Myeloma Patients
Charlotte Pawlyn et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (I-KRd) in front-line treatment of high-risk Multiple Myeloma: Results of the Safety Run-In cohort in the phase II, multicenter GMMG-CONCEPT trial
Katja Weisel et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
A phase 1b study of once-weekly carfilzomib combined with lenalido-mide and dexamethasone (wKRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM)
Melissa Alsina et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carthadex (KTd)-trial update?
Monika Engelhardt et al.
HAEMATOLOGICA (2019)
Efficacy and Safety of Carfilzomib at 56mg/m2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study
Kwee Yong et al.
BLOOD (2019)
Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study
Ola Landgren et al.
BLOOD (2019)
Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
Luciano J. Costa et al.
BLOOD (2019)
Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma
Peter A. Forsberg et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study
M. O'Dwyer et al.
BLOOD ADVANCES (2019)
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma
S. Bringhen et al.
LEUKEMIA (2018)
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)
Sara Bringhen et al.
HAEMATOLOGICA (2018)
Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial
Dickran Kazandjian et al.
JAMA ONCOLOGY (2018)
MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone
Neha Korde et al.
BLOOD (2018)
Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologist
Thierry Facon et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2018)
An overview of the role of carfilzomib in the treatment of multiple myeloma
Dimitrios C. Ziogas et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)
Ralph V. Boccia et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
A practical review on carfilzomib in multiple myeloma
Eli Muchtar et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyeLome (IFM) Krd Phase II Study
Murielle Roussel et al.
BLOOD (2016)
Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)
Todd Zimmerman et al.
BLOOD (2016)
Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma
Philippe Moreau et al.
BLOOD (2015)
Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma
Joseph R. Mikhael et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling
Fabrizio Accardi et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
Neha Korde et al.
JAMA ONCOLOGY (2015)
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
Sara Bringhen et al.
BLOOD (2014)
Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial
Diana M. Gibb
LANCET (2013)
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
Andrzej J. Jakubowiak et al.
BLOOD (2012)
Share Paper
